Regarding the 65th Meeting of the Specified Diseases Review Committee of the Disease Control Department of the Health Sciences Council

News Highlights

The 65th meeting of the Specified Diseases Review Committee of the Disease Control Department of the Health Sciences Council was held. This committee is a forum for important discussions concerning the core of intractable disease countermeasures, such as reviewing the definition of specified intractable diseases and the diseases eligible for medical expense subsidies. Moving forward, there is a possibility of new intractable diseases being designated or existing diseases being reviewed, which is expected to impact the medical treatment systems and management strategies of medical institutions.

M&A Medical Editorial Department’s Perspective

The convening of the Specified Diseases Review Committee can have a direct impact on the management of individual medical institutions. For example, the designation of new intractable diseases or the expansion of eligibility for existing diseases holds the potential to become a new revenue stream for clinics and hospitals specializing in those conditions. On the other hand, management decisions such as securing specialists and investing in equipment will be essential. Depending on the discussions at this committee meeting, scenarios where the business value of medical institutions belonging to specific regions or departments significantly fluctuates are conceivable. From an M&A perspective, options such as acquisition strategies looking towards future business expansion, or conversely, divesting business to strengthen specialization, become more realistic. The impact will likely be more pronounced, particularly in regions with high treatment rates for patients with specified intractable diseases or in areas where specialists for these diseases are scarce.

Points Raised by This News

• Review of specified intractable diseases directly impacts the revenue structure of medical institutions treating the targeted diseases.
• The designation of new intractable diseases may lead to an increase in the business value of specialized clinics and hospitals.
• Trends in intractable disease countermeasures influence the acquisition and divestiture strategies of medical institutions in M&A.
• In areas with a shortage of specialists, the need for business succession related to specified intractable diseases may increase.

Practical Questions Arising from This News

• What specific intractable diseases are likely to be added or removed by this committee meeting?
• With the expansion of eligibility for specified intractable diseases, what level of revenue can be expected for specialized outpatient services like ours?
• How is the M&A market for medical institutions specializing in specified intractable diseases expected to move in the future?

If You Feel “Should I Consult Too?”

Please consult with an expert to consider whether the diseases your institution treats have the potential to be added or changed to specified intractable diseases in the future, and how preparing to accept patients with specified intractable diseases and strengthening specialization can lead to future business continuity and expansion. Especially if you are considering future business succession or M&A, changes in the environment surrounding specified intractable diseases can be a crucial factor influencing your institution’s business value.

M&A Medical (CentralMedience Inc.) supports the business succession of medical corporations, hospitals, and clinics with a complete success-fee-based system as an M&A support institution certified by the Small and Medium Enterprise Agency. Consultations are accepted with strict confidentiality. Free consultations are available here.